This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jan 21, 2026
•
9 min read
🧬 GSK acquires RAPT Therapeutics for $2.2B - targeting food allergy market with ozureprubart antibody, Roche doubles Genentech's North Carolina facility investment to $2B targeting obesity treatments by 2029, Exciva raises $59M Series B for neuropsychiatric treatments + Alzheimer's agitation therapy, Moderna and Merck & Co.'s intismeran autogene plus Keytruda maintains 49% risk reduction in advanced melanoma Ph2 study, Pfizer sell ViiV Healthcare stake to Shionogi in deal worth $2.1 billion
Jan 20, 2026
6 min read
🧬 Sharp Services invests over €20 million ($23.2M) to expand European injectables packaging capacity amid strong market demand, Cytotheryx raises $60M Series A to develop cell therapy treatments for liver disease, Nxera Pharma reports positive Ph3 results for Quviviq (daridorexant) targeting orexin receptors in insomnia patients, Syngene International + Bristol Myers Squibb extend research collaboration through 2035 covering discovery to commercialization, Astellas Pharma's zolbetuximab receives Scottish Medicines Consortium approval for CLDN18.2-positive gastric cancer treatment
Jan 19, 2026
7 min read
🧬 Novo Nordisk's oral Wegovy shows strong early prescription uptake - outpacing rival Eli Lilly's Zepbound launch, AgomAb Therapeutics files $100M US IPO - ALK5 inhibitors for inflammatory diseases, ImmunityBio reports promising Ph1 results for CD19 CAR-NK cell therapy in Waldenström macroglobulinemia, AbelZeta + AstraZeneca expand GPC3 CAR-T therapy partnership with $630M China rights acquisition, Sobi's Aspaveli (pegcetacoplan) receives EU approval for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
Jan 16, 2026
🧬 Novo Nordisk Foundation commits $856M funding for Danish life science incubator BioInnovation Institute, Sanofi reportedly prepares renewed takeover bid for Ocular Therapeutix after rejecting $16-per-share offer, Oxford Biomedica confirms takeover talks with private equity group EQT after rejecting previous low offers, BD invests $110M to expand Nebraska syringe production amid rising GLP-1 and biologics demand, Ocugen's OCU410 gene therapy shows 46% lesion growth reduction in Ph2 trial for geographic atrophy, BMS Immunai collaborate on AI-powered immune system analysis using AMICA-OS platform (terms undisclosed), Sanofi's Myqorzo (aficamten) and Redemplo (plozasiran) win China approval for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome
Jan 15, 2026
🧬 Novo Nordisk refocuses core business on diabetes and obesity - pulling back from unrelated indications, Eli Lilly expects second-quarter 2026 FDA decision on orforglipron obesity pill with priority voucher review, Sino Biopharmaceutical to acquire Hygieia Biomedical for $172M to expand siRNA chronic disease pipeline, Servier launches Servier Ventures with €200M ($232.8M) fund for oncology/neurology biotechs, Caldera Therapeutics launches with $112.5M funding and dual-targeting inflammatory bowel disease drug from China's Qyuns, Johnson & Johnson's Tecvayli (teclistamab) shows Ph3 success targeting BCMA in relapsed multiple myeloma patients, Jazz Pharmaceuticals sells priority review voucher from Modeyso approval for $200 million
Jan 14, 2026
10 min read
🧬 AbbVie commits $100B US R&D investment over 10 years - wins tariff and pricing exemptions, AstraZeneca acquires Modella AI to integrate multimodal foundation models into its oncology R&D operations, Proxima raises $80M seed for AI-powered proximity-based therapeutics for undruggable targets, Illumina + AstraZeneca + Merck & Co. + Eli Lilly partner on Billion Cell Atlas for AI drug discovery, Nuclera extends Series C to $87M for antibody engineering platform development, ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept) shows positive Ph2/Ph3 results in non-small cell lung cancer, Novartis + Zonsen PepLib Biotech partner on peptide-based radiopharmaceutical asset for $50M upfront plus milestones, Sentynl Therapeutics and Fortress Biotech receive FDA approval for Zycubo targeting ATP7A protein for Menkes disease
Jan 13, 2026
11 min read
🧬 Eli Lilly + NVIDIA jointly invest $1B in AI co-innovation lab for drug discovery acceleration, Eli Lilly reportedly ready with €15B bid to acquire Abivax for ulcerative colitis drug obefazimod, Novartis + SciNeuro Pharmaceuticals partner on Alzheimer's anti-amyloid antibody program for $165M upfront + $1.5B milestones, Cellares expands cell therapy factory-in-a-box operations to Europe with new Netherlands manufacturing facility lease, Oricell Therapeutics raises $70M Series C to accelerate solid tumor CAR-T therapies development, Moderna hits $1.9B 2025 revenue goal while cutting operating expenses faster than expected amid cost reduction drive, Lynk Pharmaceuticals' zemprocitinib (LNK01001) hits Ph3 primary endpoint for JAK1 inhibition in rheumatoid arthritis, Sanofi's Teizeild (teplizumab) wins EU approval to delay onset of type 1 diabetes following Ph2 success
Jan 12, 2026
🧬 Merck & Co. reportedly in talks to acquire Revolution Medicines for $28-32B amid competing buyout rumors, Roche + MediLink partner on B7H3-targeted ADC YL201 - $570M upfront and near-term milestones, Orca Bio raises $250M Series F for cell therapy commercialization and pipeline advancement, Novartis to build fourth US radioligand therapy manufacturing facility in Florida as part of $23B investment, AirNexis Therapeutics debuts with $200M series A funding to develop China-sourced COPD therapy AN01, Eikon Therapeutics files IPO for their immuno-responsive cancer treatments including TLR7/8 dual-agonist, Eli Lilly + Chai Discovery partner on AI drug design using Chai 1 and Chai 2 platforms
Jan 9, 2026
🧬 Parabilis raises $305M Series F, advancing cancer drug zolucatetide toward registration, Genmab + Anthropic partner on Claude-powered AI systems for clinical development operations, Eli Lilly's Zepbound (tirzepatide)-Taltz combo shows Ph3b success in psoriatic arthritis patients with obesity, Pfizer + Gordian Bio partner on obesity target discovery using in vivo genomics platform, Massachusetts biopharma VC funding hits $6.85B in 2025 & analysts optimistic for 2026 recovery, Aktis raises $318M IPO - developing radiopharmaceutical drugs targeting cancer tumors, Alveus Therapeutics launches with $160M Series A to advance MariTide-like obesity drug ALV-100
Jan 8, 2026
🧬 Eli Lilly to acquire Ventyx Biosciences for $1.2B to expand oral immune drug pipeline, Soley Therapeutics raises $200M Series C to advance oncology assets to clinic, GSK's bepirovirsen shows potential as first finite six-month treatment for chronic hepatitis B, Rakuten Medical raises $100M funding for light-based cancer therapy toward 2028 FDA filing, Poplar Therapeutics launches with $50M Series A to advance PHB-050 as a next-generation anti-IgE therapy for food allergy, Celltrion opens first US manufacturing plant in New Jersey for $330M to stabilize supply chain, Relation Therapeutics + Deerfield team up to build newcos around AI-identified drug targets, Eli Lilly + InduPro partner on cancer treatment discovery using AI platform with a total potential deal size of $950M
Jan 7, 2026
🧬 Amgen to acquire Dark Blue Therapeutics for up to $840M to expand protein-degrading cancer pipeline, Arrowhead Pharma's ARO-INHBE doubles tirzepatide weight loss in type 2 diabetes patients in Ph1/Ph2a trial, Pfizer + Cartography Biosciences partner on tumor-selective antigen discovery - $65M upfront w/ $850M total potential, GSK's Exdensur (depemokimab) wins Japan approval for severe asthma and chronic rhinosinusitis with nasal polyps, Eli Lilly + Nimbus Therapeutics partner on preclinical oral obesity drug - $55M upfront + $1.3B biobucks, Bright Minds Biosciences' BMB-101 shows positive Ph2 results for drug-resistant absence seizures and developmental epilepsies, Mediar Therapeutics raises $76M Series B for clinical trials of fibrosis drugs
Jan 6, 2026
8 min read
🧬 Novo Nordisk launches oral Wegovy in US at $149 monthly out-of-pocket price - shares rise 2.6%, Moderna files for approval of mRNA-1010 seasonal influenza vaccine for adults aged 50 and older, Aktis Oncology aims for $209M IPO, developing miniprotein radiopharmaceuticals for cancer, Servier + Insilico Medicine partner on AI-driven oncology drug discovery in $32M upfront & $888M total deal, Incyte's Monjuvi (tafasitamab) shows Ph3 success in first-line diffuse large B-cell lymphoma - FDA filing planned, Neumora Therapeutics reports positive Ph1b results for NMRA-511 vasopressin 1a receptor antagonist in Alzheimer's disease agitation, Daiichi Sankyo plans $1.9B global Enhertu manufacturing investments across Japan, U.S., Germany, China
